Ten years after the 2005 Paris Declaration on Aid Effectiveness reported on the need for better coordination in the global fight against disease, global pharmaceutical supply chains remain fragmented and lack coordination, facing at least 10 fundamental challenges, according to a newly published paper.
President Barack Obama is calling for an investment to move away from one-size-fits-all-medicine, toward an approach that tailors treatment to your genes. The White House said Friday that Obama will ask Congress for $215 million for what he's calling a precision medicine initiative. The ambitious goal: Scientists will assemble databases of about a million volunteers to study their genetics to learn how to individualize care.
Low doses of metformin, a widely used diabetes medication and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue Univ. study finds. Prostate cancer causes the second-highest number of cancer-related deaths in men in the U.S., and methods of treating advanced prostate cancer are limited.
A new study by Univ. of Kentucky Markey Cancer Center researchers suggests that targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat lung cancer. Cancer cells undergo metabolic alterations to meet the increased energy demands that support their excess growth and survival.
Lori Simons took the bright orange pill at 3 a.m. Eight hours later, doctors sliced into her brain, looking for signs that the drug was working. She is taking part in one of the most unusual cancer experiments in the nation. With special permission from the Food and Drug Administration and multiple drug companies, an Arizona hospital is testing medicines very early in development and never tried on brain tumors before.
Two new drug compounds appear to be effective in treating endometriosis, a disorder that, like MS, is driven by estrogen and inflammation, scientists report in Science Translational Medicine. The researchers hope to eventually use the new compounds and others like them to treat a variety of disorders linked to estrogen signaling and inflammation.
As predators go, cone snails are slow moving and lack the typical fighting parts. They’ve made up for it by producing a vast array of fast-acting toxins that target the nervous systems of prey. A new study reveals that some cone snails add a weaponized form of insulin to the venom cocktail they use to disable fish.
More efficient medical treatments could be developed thanks to a new method for triggering the rearrangement of chemical particles. The new method, developed at the Univ. of Warwick, uses two “parent” nanoparticles that are designed to interact only when in proximity to each other and trigger the release of drug molecules contained within both.
A regime of anti-HIV drugs has the potential to protect against infection in the first place. But real life can interfere; the effectiveness of this prophylactic approach declines if the medications aren’t taken as prescribed. HIV researchers hope a new compound, known as cabotegravir, could make dosing easier for some because the drug would be administered by injection once every three months.
Chemists have made a significant advancement to directly functionalize C-H bonds in natural products by selectively installing new carbon-carbon bonds into highly complex alkaloids and nitrogen-containing drug molecules. C-H functionalization is a much more streamlined process than traditional organic chemistry, holding the potential to greatly reduce the time and number of steps needed to create derivatives of natural products.
In the midst of a worrisome flu season, health officials are pushing doctors to prescribe antiviral medicines. The Centers for Disease Control and Prevention on Friday sent a new alert to doctors, advising prompt use of Tamiflu and other antivirals for hospitalized flu patients and those at higher risk for complications like pneumonia.
For years, pathogens’ resistance to antibiotics has put them one step ahead of researchers, which is causing a public health crisis, according to Northeastern Univ. Distinguished Prof. Kim Lewis. But in new research, Lewis and his colleagues present a newly discovered antibiotic that eliminates pathogens without encountering any detectable resistance.
A major barrier to finding a cure for HIV/AIDS is the presence of latent HIV in the cells of chronically infected individuals. But a team of Yale and Johns Hopkins researchers may have pinpointed a strategy for eliminating the residual virus. Despite treatment with antiretroviral therapy, HIV persists in patients in a latent reservoir.
Researchers at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows promise for targeting lung-specific diseases, such as influenza, pneumonia and tuberculosis.
Federal health experts have unanimously endorsed a Novartis drug which is expected to become the first lower-cost copy of a biotech drug to reach the U.S. market. A panel of FDA experts ruled that the company's version of Neupogen is highly similar to Amgen's original blockbuster biotech drug, which is used to boost blood cells that help cancer patients fight off infections.
An international team of researchers has developed a drug delivery technique that utilizes graphene strips as “flying carpets” to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.
New research findings point toward a class of compounds that could be effective in combating infections caused by enterovirus D68, which has stricken children with serious respiratory infections in the U.S. and elsewhere. The researchers used x-ray crystallography to learn the precise structure of the original strain of EV-D68 on its own and when bound to an anti-viral compound called "pleconaril."
With drug-resistant bacteria on the rise, even common infections that were easily controlled for decades are proving trickier to treat with standard antibiotics. New drugs are desperately needed, but so are ways to maximize the effective lifespan of these drugs. To accomplish that, Duke Univ. researchers used software they developed to predict a constantly evolving infectious bacterium's countermoves to one of these new drugs ahead of time.
A company that is developing new anti-viral drugs hopes it will have a cure for Ebola, which is still in the research phase, put on the fast track for development in the fight against the disease. NanoViricides, whose headquarters are in West Haven, opened its research and development lab in July. The company, with a net worth of $250 million, employs more than 20 and expects to double that in the next two years.
The tequila sure looks real, so do the beer taps. Inside the hospital at the National Institutes of Health, researchers are testing a possible new treatment to help heavy drinkers cut back, using a replica of a fully stocked bar. The idea: Sitting in the dimly lit bar-laboratory should cue the volunteers' brains to crave a drink, and help determine if the experimental pill counters that urge.
The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years. FDA drug approvals are considered a barometer of industry innovation and the federal government's efficiency in reviewing new therapies. Last year's total was the most since the all-time high of 53 drugs approved in 1996.
Researchers at Swinburne University of Technology have discovered an instability in gold nanoparticles that is critical for their application in future technology. Gold nanorods are important building blocks for future applications in solar cells, cancer therapy and optical circuitry.
Scientists often test drugs in mice. Now some cancer patients are doing the same—with the hope of curing their own disease. They are paying a private lab to breed mice that carry bits of their own tumors so treatments can be tried first on the customized rodents. The idea is to see which drugs might work best on a specific person's cancer.
As the health care industry is undergoing a rapid transformation driven by evolving economic and regulatory demands, the biopharmaceutical industry also faces numerous challenges in meeting the needs of patients around the globe. Emerging markets are faced with the challenges of ensuring access to innovative, personalized treatments for patients with critical or rare conditions.
Nearly half of all U.S. adults, nearly 117 million individuals, are living with one or more chronic health conditions. This has become the age of chronic disease, and achieving better outcomes depends on developing tools for research and clinical care that efficiently and accurately address the complex diseases we face today.